AngioDynamics' NanoKnife FDA clearance boosts its potential in cancer treatment. Read why ANGO stock is a buy with its growth ...

AngioDynamics (ANGO) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to loss of $0.05 per share a year ago. These figures are ...

Q2 2025 Earnings Conference Call January 8, 2025 8:00 AM ETCompany ParticipantsJim Clemmer - President and Chief ...

An announcement from AngioDynamics ( (ANGO) ) is now available.Stay Ahead of the Market:Discover outperforming stocks and invest smarter with ...

AngioDynamics Inc. ANGO) on Wednesday reported a loss of $10.7 million in its fiscal second quarter. On a per-share basis, the Latham, New York-based company said it had a loss of 26 cents.

Discover outperforming stocks and invest smarter with Top Smart Score StocksFilter, analyze, and streamline your ...

In August 2024, President Bola Ahmed Tinubu appointed Mr. Michael Hadi Ango as the Acting Executive Chairman of the Federal ...

AngioDynamics Inc (NASDAQ:ANGO) is set to release its Q2 2025 earnings on Jan 8, 2025. The consensus estimate for Q2 2025 ...